On Invalid Date, Arcutis Biotherapeutics (NASDAQ: ARQT) reported Q4 2023 earnings per share (EPS) of -$0.59, up 48.25% year over year. Total Arcutis Biotherapeutics earnings for the quarter were -$66.28 million. In the same quarter last year, Arcutis Biotherapeutics's earnings per share (EPS) was -$1.14.
As of Q1 2024, Arcutis Biotherapeutics's earnings has grown year over year. Arcutis Biotherapeutics's earnings in the past year totalled -$262.14 million.
What is ARQT's earnings date?
Arcutis Biotherapeutics's earnings date is Invalid Date. Add ARQT to your watchlist to be reminded of ARQT's next earnings announcement.
What was ARQT's revenue last quarter?
On Invalid Date, Arcutis Biotherapeutics (NASDAQ: ARQT) reported Q4 2023 revenue of $13.53 million up 356.81% year over year. In the same quarter last year, Arcutis Biotherapeutics's revenue was $2.96 million.
What was ARQT's revenue growth in the past year?
As of Q1 2024, Arcutis Biotherapeutics's revenue has grown 1,517.09% year over year. This is 1,347.79 percentage points higher than the US Biotechnology industry revenue growth rate of 169.3%. Arcutis Biotherapeutics's revenue in the past year totalled $59.61 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.